Aptamers That Target Cxcl9

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention presents novel aptamers, which are short single-stranded nucleic acids designed to specifically bind to the chemokine CXCL9 (and CXCL11) with high affinity and selectivity. These aptamers can be used in diagnostic assays to non-invasively detect or monitor kidney transplant rejection by identifying these early biomarkers in patients, potentially through urine or blood samples. The aptamers are chemically synthesized and can be used on their own or in combination with antibodies for improved diagnostic performance.

Use CasesContent extracted from patent full text and abstract with AI.

• Point-of-care diagnostic tests for early detection of kidney transplant rejection using blood or urine samples.
• Non-invasive monitoring of transplant patients to predict possible organ rejection events, potentially replacing or reducing the need for biopsies.
• Development of diagnostic kits or assays (such as lateral flow devices or ELONA) for hospital or home use in transplant aftercare.
• Use as research tools for studying chemokine-mediated inflammation or organ rejection mechanisms.
• Potential as a delivery system for therapeutic agents targeted to inflammation sites, such as in kidney transplants.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a non-invasive, sensitive, and specific method to detect kidney transplant rejection, reducing dependence on riskier biopsy procedures.
• Aptamers have high affinity and selectivity for CXCL9 and CXCL11, ensuring accuracy in detection.
• Can be synthesized chemically, increasing reproducibility and batch consistency compared to antibodies.
• Aptamers are stable and can function under a wide range of conditions, including those found in human urine or blood.
• Compatibility with various diagnostic platforms (e.g., fluorescence, colorimetric assays, lateral flow assays) and potential for rapid, point-of-care testing.
• Potential to improve patient outcomes by enabling earlier intervention and treatment adjustment for transplant recipients.
• Possibility to be combined with other biomarkers or antibodies to further increase diagnostic accuracy.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, preferably comprising or consisting of a nucleotide sequence SEQ ID NO: 4-6. The invention further relates to a composition comprising the aptamer, and the use of the aptamer as a medicament or a diagnostic reagent, particularly for use in the detection or diagnosing of a rejection of a renal allograft.